Sarepta Therapeutics Stock Price, News & Analysis (NASDAQ:SRPT)

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 3 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SRPT shares.
View SRPT analyst ratings or view top-rated stocks.

18 equities research analysts have issued 1 year target prices for Sarepta Therapeutics' stock. Their SRPT share price targets range from $40.00 to $224.00. On average, they anticipate the company's share price to reach $153.10 in the next year. This suggests a possible upside of 75.9% from the stock's current price.
View analysts price targets for SRPT or view top-rated stocks among Wall Street analysts.

Sarepta Therapeutics' stock was trading at $129.58 on January 1st, 2023. Since then, SRPT shares have decreased by 32.8% and is now trading at $87.03.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our SRPT earnings forecast.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) released its quarterly earnings results on Wednesday, November, 1st. The biotechnology company reported $0.37 EPS for the quarter, beating the consensus estimate of ($1.63) by $2.00. The biotechnology company had revenue of $331.80 million for the quarter, compared to analysts' expectations of $285.33 million. Sarepta Therapeutics had a negative trailing twelve-month return on equity of 46.23% and a negative net margin of 62.52%. The firm's revenue for the quarter was up 44.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($2.94) EPS.

ETFs with the largest weight of Sarepta Therapeutics (NASDAQ:SRPT) stock in their portfolio include Morningstar US Small Growth (MSGR), Global X Genomics & Biotechnology ETF (GNOM), iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Principal Healthcare Innovators ETF (BTEC), VanEck Biotech ETF (BBH), Franklin Genomic Advancements ETF (HELX) and American Century Mid Cap Growth Impact (MID).

15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS).

Sarepta Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (4.18%), Deutsche Bank AG (1.14%), Deutsche Bank AG (1.14%), Federated Hermes Inc. (1.03%), Westfield Capital Management Co. LP (0.86%) and Charles Schwab Investment Management Inc. (0.60%). Insiders that own company stock include Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, Louise Rodino-Klapac, M Kathleen Behrens, Michael Andrew Chambers, Richard Barry and Stephen Mayo.
View institutional ownership trends.

Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.